Global X-Linked Hypophosphatemia Market Research Report Forecast to 2025

Array
(
    [id] => 1796561
    [discount] => PDF-18-ENTERPRISE WIDE LICENCE-20------
    [isbn] => 
    [title] => Global X-Linked Hypophosphatemia Market Research Report Forecast to 2025
    [upcommingtext] => 
    [seo_url] => global-x-linked-hypophosphatemia-market-research-report-forecast
    [shortdesc] => 
    [meta_title] => Global X-Linked Hypophosphatemia Market Research Report Forecast to 2025
    [keyword] => Global X-Linked Hypophosphatemia Market Research Report Forecast to 2025
    [description] => X-Linked Hypophosphatemia Market Research Report - Global Forecast till 2025
Global X-Linked Hypophosphatemia Market: By Treatment (Medication, Surgical, or Orthopedic Treatment), End User (Hospitals and Clinics, Research Centers) & Region (Americas,
    [curr] => USD
    [category] => 1200
    [publisher] => 182
    [published_date] => 2019-11-22
    [country] => 230
    [author_name] => 
    [page_num] => 84
    [abstract] => X-Linked Hypophosphatemia Market Research Report - Global Forecast till 2025
Global X-Linked Hypophosphatemia Market: By Treatment (Medication, Surgical, or Orthopedic Treatment), End User (Hospitals and Clinics, Research Centers) & Region (Americas, Europe, Asia-Pacific & RoW) - Forecast till 2025

Market Analysis
XLH is an inherited phosphate metabolism disorder in which inactivating mutations of the PHEX gene lead to local and systemic effects such as impaired growth, rickets, hearing difficulties, enthesopathy, osteomalacia, bone pain, bone abnormalities, spontaneous dental abscesses, osteoarthritis, and muscular dysfunction. The growing cases of XLH in developing countries and developed countries, the global XLH market is expected to grow steadily during the forecast period. For instance, according to a European Journal of Endocrinology statistics released in 2016, the incidence of XLH is estimated to be 3.9 per 100,000 live births and has a incidence of 4.8 per 100,000 people. Also, according to a study published in May 2016 by NIHR Horizon Scanning Research & Intelligence Centre, XLH affected more than 500 children in the UK. X-linked hypophosphatemia (XLH) is an inherited condition characterized by lower levels of phosphate in the blood. The phosphate levels lessen as it is exceptionally processed for the kidneys, resulting in the loss of phosphate over the urine (phosphate wasting) and leads to soft and weak bones, causing rickets. XLH is generally diagnosed in childhood, and symptoms have lowered or bent legs, short stature, bone pain, and heavy dental pain. XLH is due to mutations PHEX gene on the X chromosome, and the legacy of the X-linked is the dominant. The treatment generally involves supplements of phosphate and high-dose calcitriol (an active form of vitamin D) and may include growth hormones and remedial surgery. Main factors accountable for driving the market are growing a prevalence of XLH, growing awareness about XLH. However, negative psychological and emotional impacts of having X-linked hypophosphatemia, post-operative complications, unfavourable drug price control policies in many countries, increasing penetration of counterfeit drugs, and complex license renewal procedures are hindering the growth of the global X-linked hypophosphatemia market. The Global X-Linked Hypophosphatemia Market is forecast to register a CAGR of 3.6% in order to achieve USD 40,309.1 Thousand by the year 2025. In the Same Way, according to statistics published in 2017 by the Food and Drug Administration (FDA), XLH had an impact on an approximate of 3,000 children and 12,000 adults in the US. And according to a report published in the year 2017 by the National Institute for Health and Care Excellence, there were around 250 children and young people with XLH in England, and up to 2,500 adults, till date. Thus, total market growth is expected to rise due to rising incidence of XLH, which required enough drugs and therapies for treatment. The X-linked hypophosphatemia (XLH) market by treatment has been divided into medication and Surgical or orthopedic treatment. The X-linked hypophosphatemia market is categorized by the end user into hospitals and clinics and research facilities. The research centers segment is expected to account for the largest market share during the forecast period attributing to the increasing prevalence of XLH, a growing awareness regarding the disease, and growing scientific activity for its treatment. The global X-linked hypophosphatemia market, according to the region, is segmented into the Americas, Europe, Asia-Pacific, and RoW. Factors such as the increasing prevalence of XLH and increasing awareness about the disorder is expected to boost the growth of the global X-Linked hypophosphatemia market.

Market Segmentation
The global X-linked hypophosphatemia (XLH) market has been segmented by treatment, by end user and by region. By treatment the Global X-Linked Hypophosphatemia Market has been segmented into Medication and Surgical or Orthopedic Treatment. Based on End User the market has been segmented into Hospitals and Clinics and Research Centres. Global X-Linked Hypophosphatemia Market based on region is split into different regions like Americas, Europe, Asia-Pacific, Middle East and Africa. America include North America (US, Canada and South America), Europe (covering Germany, UK, France, Spain, Italy and Rest of Europe), Asia-Pacific (covering China, India, Japan, Australia & New Zealand, Southeast Asia and Rest of Asia-Pacific), Middle East and Africa.

Regional Analysis
Geographically, the Global X-Linked Hypophosphatemia Market based on region is split into different regions like Americas, Europe, Asia-Pacific, Middle East and Africa. America include North America (US, Canada and South America), Europe (covering Germany, UK, France, Spain, Italy and Rest of Europe), Asia-Pacific (covering China, India, Japan, Australia & New Zealand, Southeast Asia and Rest of Asia-Pacific), Middle East and Africa. The XLH market in the Americas is expected to hold significant market share owing to the growing prevalence of XLH in the US and Canada and the presence of a well-established healthcare sector. Growing funding for research towards rare diseases such as XLH and the high healthcare expenditure is expected to fuel the growth of the market within the forecast period. For example, Genome Canada and the Canadian Institutes for Health Research partnered to study rare genetic disorders by using Next-Generation Sequencing (NGS) technology. In the Same Way, the International Rare Diseases Research Consortium (IRDiRC) is a Scientific Secretariat that collaborates with Orphanet. Since 2010, IRDiRC financed over 3,000 projects. Additionally, according to statistics published in the year 2017 by the Food and Drug Administration (FDA), XLH affected an approximate of 3,000 children and 12,000 adults in the US. Additionally, the increasing government funding for the healthcare sector, the increasing incidence rate of rare diseases, and research funding is expected to drive the growth of the market in this region.

Major Players
The proposed spectators in the global X-linked hypophosphatemia (XLH) market are coke manufacturers, Retailers, distributors, wholesalers, Investors and trade experts, Governments, associations, industrial bodies, etc. The major companies functioning in the global X-linked hypophosphatemia (XLH) market are concentrating on firming their global ways by entering into untouched markets. The projected onlookers are Government Research Laboratories, Independent Research Laboratories, Government and Independent Regulatory Authorities, Drug Suppliers, Research and Development (R&D) Companies, Market Research and Consulting Service Providers, Medical Research Laboratories and Academic Medical Institutes and Universities. Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Ultragenyx Pharmaceutical, Validus Pharmaceuticals LLC, Merck KGaA, Zeria Pharmaceutical Co., Ltd, Narang Medical Limited, Prospec-Tany Technogene Ltd, Smith & Nephew, and Others are some of the Major Players in the global X-linked hypophosphatemia (XLH) market. The players active in global X-linked hypophosphatemia (XLH) market are focusing on product launches, together with expanding their global footprints by going into the untapped markets. [table_of_contents] =>

1 Executive Summary
2 Market Introduction
2.1 Scope of the Study
2.2 Research Objective
2.3 List of Assumptions
3 Research Methodology
3.1 Research Methodology - X-Linked Hypophosphatemia Market
3.2 Data Mining
3.3 Secondary Research
3.3.1 Data points received from the secondary research
3.4 Primary Research
3.4.1 Data points received from surgeons, & consulting physicians
3.4.2 Data points received from the manufacturer
3.5 Forecasting Techniques
3.6 Research Methodology for Market Size Estimation X-Linked Hypophosphatemia Market:
3.6.1 Assumptions
3.7 Data Triangulation
3.8 Validation
4 Market Dynamics
4.1 Overview
4.2 Drivers
4.2.1 Increasing Prevalence Rate of XLH
4.2.2 Growing Awareness about XLH
4.2.3 Increasing Research
4.2.4 Driver Impact Analysis
4.3 Restraints
4.3.1 Side-Effects Associated with Burosumab
4.3.2 High Cost of Burosumab
4.3.3 Limited Availability of Treatment Options
4.3.4 Restraint Impact Analysis
4.4 Opportunity
4.4.1 Recent Regulatory Approvals
5 Market Factor Analysis
5.1 Value Chain Analysis
5.1.1 Overview
5.1.2 R&D
5.1.3 Manufacturing
5.1.4 Distribution and Sales
5.1.5 Post-Sales Monitoring
5.2 Porters Five Forces Model
5.2.1 Overview
5.2.2 Bargaining Power of Suppliers
5.2.3 Bargaining Power of Buyers
5.2.4 The threat of New Entrants
5.2.5 Threat of Substitutes
5.2.6 Intensity of Rivalry
6 Global X-Linked Hypophosphatemia Market, by Treatment
6.1 Introduction
6.2 Medication
6.3 Surgical or Orthopedic Treatment
7 Global X-Linked Hypophosphatemia Market, by End User
7.1 Introduction
7.2 Hospitals and Clinics
7.3 Research Centers
8 Global X-Linked Hypophosphatemia Market, by Region
8.1 Introduction
8.2 Americas
8.2.1 North America
8.2.1.1 US
8.2.1.2 Canada
8.2.2 South America
8.3 Europe
8.3.1 Germany
8.3.2 France
8.3.3 UK
8.3.4 Italy
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia-Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 South Korea
8.4.5 Australia
8.4.6 Rest of Asia-Pacific
8.5 RoW
9 Competitive landscape
9.1 Introduction
9.2 Key developments
10 Company Profiles
10.1 Ultragenyx Pharmaceutical
10.1.1 Company Overview
10.1.2 Financial Overview
10.1.3 Products/Services Offered
10.1.4 Key Developments
10.1.5 SWOT Analysis
10.1.6 Key Strategies
10.2 Validus Pharmaceuticals LLC
10.2.1 Company Overview
10.2.2 Financial Overview
10.2.3 Products/Services Offered
10.2.4 Key Developments
10.2.5 SWOT Analysis
10.2.6 Key Strategies
10.3 Prospec-Tany Technogene Ltd
10.3.1 Company Overview
10.3.2 Financial Overview
10.3.3 Products/Services Offered
10.3.4 Key Developments
10.3.5 SWOT Analysis
10.3.6 Key Strategies
10.4 Merck KGaA
10.4.1 Company Overview
10.4.2 Financial Overview
10.4.3 Products/Services Offered
10.4.4 Key Developments
10.4.5 SWOT Analysis
10.4.6 Key Strategies
10.5 Zeria Pharmaceutical Co., Ltd
10.5.1 Company Overview
10.5.2 Financial Overview
10.5.3 Products/Services Offered
10.5.4 Key Developments
10.5.5 SWOT Analysis
10.5.6 Key Strategies
10.6 Smith & Nephew
10.6.1 Company Overview
10.6.2 Financial Overview
10.6.3 Products/Services Offered
10.6.4 Key Developments
10.6.5 SWOT Analysis
10.6.6 Key Strategies
10.7 Narang Medical Limited
10.7.1 Company Overview
10.7.2 Financial Overview
10.7.3 Products/Services Offered
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.7.6 Key Strategies
10.8 Eli Lilly and Company
10.8.1 Company Overview
10.8.2 Financial Overview
10.8.3 Products/Services Offered
10.8.4 Key Developments
10.8.5 SWOT Analysis
10.8.6 Key Strategies
10.9 F. Hoffmann-La Roche Ltd
10.9.1 Company Overview
10.9.2 Financial Overview
10.9.3 Products/Services Offered
10.9.4 Key Developments
10.9.5 SWOT Analysis
10.9.6 Key Strategies
10.1 Illumina, Inc.
10.10.1 Company Overview
10.10.2 Financial Overview
10.10.3 Products/Services Offered
10.10.4 Key Developments
10.10.5 SWOT Analysis
10.10.6 Key Strategies
10.11 Biomedica Medizinprodukte GmbH
10.11.1 Company Overview
10.11.2 Financial Overview
10.11.3 Products/Services Offered
10.11.4 Key Developments
10.11.5 SWOT Analysis
10.11.6 Key Strategies
10.12 QIAGEN
10.12.1 Company Overview
10.12.2 Financial Overview
10.12.3 Products/Services Offered
10.12.4 Key Developments
10.12.5 SWOT Analysis
10.12.6 Key Strategies
11 Appendix
11.1 References
11.2 Related Reports [list_of_tables] =>

TABLE 1 LIST OF ASSUMPTIONS
TABLE 2 PORTERS FIVE FORCES ANALYSIS: GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET
TABLE 3 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 4 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET FOR MEDICATION, BY REGION 20162025 (USD THOUSANDS)
TABLE 5 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET FOR SURGICAL OR ORTHOPEDIC TREATMENT, BY REGION 20162025 (USD THOUSANDS)
TABLE 6 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 7 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET FOR HOSPITALS AND CLINICS, BY REGION 20162025 (USD THOUSANDS)
TABLE 8 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET FOR RESEARCH CENTERS, BY REGION 20162025 (USD THOUSANDS)
TABLE 9 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET, BY REGION 20162025 (USD THOUSANDS)
TABLE 10 AMERICAS: X-LINKED HYPOPHOSPHATEMIA MARKET, BY REGION 20162025 (USD THOUSANDS)
TABLE 11 AMERICAS: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 12 AMERICAS: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 13 NORTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY COUNTRY 20162025 (USD THOUSANDS)
TABLE 14 NORTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 15 NORTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 16 US: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 17 US: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 18 CANADA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 19 CANADA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 20 SOUTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 21 SOUTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 22 EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY COUNTRY/REGION 20162025 (USD THOUSANDS)
TABLE 23 EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 24 EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 25 GERMANY: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 26 GERMANY: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 27 FRANCE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 28 FRANCE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 29 UK: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 30 UK: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 31 ITALY: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 32 ITALY: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 33 SPAIN: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 34 SPAIN: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 35 REST OF EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 36 REST OF EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 37 ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET, BY COUNTRY/REGION 20162025 (USD THOUSANDS)
TABLE 38 ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 39 ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 40 CHINA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 41 CHINA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 42 JAPAN: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 43 JAPAN: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 44 INDIA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 45 INDIA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 46 SOUTH KOREA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 47 SOUTH KOREA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 48 ASUTRALIA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 49 ASUTRALIA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 50 ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 51 ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 52 ROW: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 53 ROW: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 54 KEY DEVELOPMENTS, BY PLAYERS IN THE MARKET [list_of_figures] =>

FIGURE 1 MARKET SYNOPSIS
FIGURE 2 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET: STRUCTURE
FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH
FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL GROWTH HORMONE MARKET
FIGURE 5 DRIVER IMPACT ANALYSIS
FIGURE 6 RESTRAINT IMPACT ANALYSIS
FIGURE 7 SUPPLY CHAIN: GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET
FIGURE 8 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2018 & 2025 (USD THOUSANDS)
FIGURE 9 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2018 & 2025 (USD THOUSANDS)
FIGURE 10 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET SHARE, BY REGION 2018 (%)
FIGURE 11 AMERICAS: X-LINKED HYPOPHOSPHATEMIA MARKET SHARE, BY REGION 2018 (%)
FIGURE 12 NORTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET SHARE, BY COUNTRY 2018 (%)
FIGURE 13 EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET SHARE, BY COUNTRY/REGION 2018 (%)
FIGURE 14 ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET SHARE, BY COUNTRY/REGION 2018 (%)
FIGURE 15 MAJOR PLAYERSCATEGORY-WISE SHARE OF KEY DEVELOPMENTS [sample_page] => [brochure] => [new_price] => PDF-4450-ENTERPRISE WIDE LICENCE-6250-ENTERPRISE WIDE LICENCE--ENTERPRISE WIDE LICENCE--ENTERPRISE WIDE LICENCE--ENTERPRISE WIDE LICENCE--Multi User Licence- )
discount aarkstore
X-Linked Hypophosphatemia Market Research Report - Global Forecast till 2025
Global X-Linked Hypophosphatemia Market: By Treatment (Medication, Surgical, or Orthopedic Treatment), End User (Hospitals and Clinics, Research Centers) & Region (Americas, Europe, Asia-Pacific & RoW) - Forecast till 2025

Market Analysis
XLH is an inherited phosphate metabolism disorder in which inactivating mutations of the PHEX gene lead to local and systemic effects such as impaired growth, rickets, hearing difficulties, enthesopathy, osteomalacia, bone pain, bone abnormalities, spontaneous dental abscesses, osteoarthritis, and muscular dysfunction. The growing cases of XLH in developing countries and developed countries, the global XLH market is expected to grow steadily during the forecast period. For instance, according to a European Journal of Endocrinology statistics released in 2016, the incidence of XLH is estimated to be 3.9 per 100,000 live births and has a incidence of 4.8 per 100,000 people. Also, according to a study published in May 2016 by NIHR Horizon Scanning Research & Intelligence Centre, XLH affected more than 500 children in the UK. X-linked hypophosphatemia (XLH) is an inherited condition characterized by lower levels of phosphate in the blood. The phosphate levels lessen as it is exceptionally processed for the kidneys, resulting in the loss of phosphate over the urine (phosphate wasting) and leads to soft and weak bones, causing rickets. XLH is generally diagnosed in childhood, and symptoms have lowered or bent legs, short stature, bone pain, and heavy dental pain. XLH is due to mutations PHEX gene on the X chromosome, and the legacy of the X-linked is the dominant. The treatment generally involves supplements of phosphate and high-dose calcitriol (an active form of vitamin D) and may include growth hormones and remedial surgery. Main factors accountable for driving the market are growing a prevalence of XLH, growing awareness about XLH. However, negative psychological and emotional impacts of having X-linked hypophosphatemia, post-operative complications, unfavourable drug price control policies in many countries, increasing penetration of counterfeit drugs, and complex license renewal procedures are hindering the growth of the global X-linked hypophosphatemia market. The Global X-Linked Hypophosphatemia Market is forecast to register a CAGR of 3.6% in order to achieve USD 40,309.1 Thousand by the year 2025. In the Same Way, according to statistics published in 2017 by the Food and Drug Administration (FDA), XLH had an impact on an approximate of 3,000 children and 12,000 adults in the US. And according to a report published in the year 2017 by the National Institute for Health and Care Excellence, there were around 250 children and young people with XLH in England, and up to 2,500 adults, till date. Thus, total market growth is expected to rise due to rising incidence of XLH, which required enough drugs and therapies for treatment. The X-linked hypophosphatemia (XLH) market by treatment has been divided into medication and Surgical or orthopedic treatment. The X-linked hypophosphatemia market is categorized by the end user into hospitals and clinics and research facilities. The research centers segment is expected to account for the largest market share during the forecast period attributing to the increasing prevalence of XLH, a growing awareness regarding the disease, and growing scientific activity for its treatment. The global X-linked hypophosphatemia market, according to the region, is segmented into the Americas, Europe, Asia-Pacific, and RoW. Factors such as the increasing prevalence of XLH and increasing awareness about the disorder is expected to boost the growth of the global X-Linked hypophosphatemia market.

Market Segmentation
The global X-linked hypophosphatemia (XLH) market has been segmented by treatment, by end user and by region. By treatment the Global X-Linked Hypophosphatemia Market has been segmented into Medication and Surgical or Orthopedic Treatment. Based on End User the market has been segmented into Hospitals and Clinics and Research Centres. Global X-Linked Hypophosphatemia Market based on region is split into different regions like Americas, Europe, Asia-Pacific, Middle East and Africa. America include North America (US, Canada and South America), Europe (covering Germany, UK, France, Spain, Italy and Rest of Europe), Asia-Pacific (covering China, India, Japan, Australia & New Zealand, Southeast Asia and Rest of Asia-Pacific), Middle East and Africa.

Regional Analysis
Geographically, the Global X-Linked Hypophosphatemia Market based on region is split into different regions like Americas, Europe, Asia-Pacific, Middle East and Africa. America include North America (US, Canada and South America), Europe (covering Germany, UK, France, Spain, Italy and Rest of Europe), Asia-Pacific (covering China, India, Japan, Australia & New Zealand, Southeast Asia and Rest of Asia-Pacific), Middle East and Africa. The XLH market in the Americas is expected to hold significant market share owing to the growing prevalence of XLH in the US and Canada and the presence of a well-established healthcare sector. Growing funding for research towards rare diseases such as XLH and the high healthcare expenditure is expected to fuel the growth of the market within the forecast period. For example, Genome Canada and the Canadian Institutes for Health Research partnered to study rare genetic disorders by using Next-Generation Sequencing (NGS) technology. In the Same Way, the International Rare Diseases Research Consortium (IRDiRC) is a Scientific Secretariat that collaborates with Orphanet. Since 2010, IRDiRC financed over 3,000 projects. Additionally, according to statistics published in the year 2017 by the Food and Drug Administration (FDA), XLH affected an approximate of 3,000 children and 12,000 adults in the US. Additionally, the increasing government funding for the healthcare sector, the increasing incidence rate of rare diseases, and research funding is expected to drive the growth of the market in this region.

Major Players
The proposed spectators in the global X-linked hypophosphatemia (XLH) market are coke manufacturers, Retailers, distributors, wholesalers, Investors and trade experts, Governments, associations, industrial bodies, etc. The major companies functioning in the global X-linked hypophosphatemia (XLH) market are concentrating on firming their global ways by entering into untouched markets. The projected onlookers are Government Research Laboratories, Independent Research Laboratories, Government and Independent Regulatory Authorities, Drug Suppliers, Research and Development (R&D) Companies, Market Research and Consulting Service Providers, Medical Research Laboratories and Academic Medical Institutes and Universities. Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Ultragenyx Pharmaceutical, Validus Pharmaceuticals LLC, Merck KGaA, Zeria Pharmaceutical Co., Ltd, Narang Medical Limited, Prospec-Tany Technogene Ltd, Smith & Nephew, and Others are some of the Major Players in the global X-linked hypophosphatemia (XLH) market. The players active in global X-linked hypophosphatemia (XLH) market are focusing on product launches, together with expanding their global footprints by going into the untapped markets.


1Executive Summary
2Market Introduction
2.1Scope of the Study
2.2Research Objective
2.3List of Assumptions
3Research Methodology
3.1Research Methodology - X-Linked Hypophosphatemia Market
3.2Data Mining
3.3Secondary Research
3.3.1Data points received from the secondary research
3.4Primary Research
3.4.1Data points received from surgeons, & consulting physicians
3.4.2Data points received from the manufacturer
3.5Forecasting Techniques
3.6Research Methodology for Market Size Estimation X-Linked Hypophosphatemia Market:
3.6.1Assumptions
3.7Data Triangulation
3.8Validation
4Market Dynamics
4.1Overview
4.2Drivers
4.2.1Increasing Prevalence Rate of XLH
4.2.2Growing Awareness about XLH
4.2.3Increasing Research
4.2.4Driver Impact Analysis
4.3Restraints
4.3.1Side-Effects Associated with Burosumab
4.3.2High Cost of Burosumab
4.3.3Limited Availability of Treatment Options
4.3.4Restraint Impact Analysis
4.4Opportunity
4.4.1Recent Regulatory Approvals
5Market Factor Analysis
5.1Value Chain Analysis
5.1.1Overview
5.1.2R&D
5.1.3Manufacturing
5.1.4Distribution and Sales
5.1.5Post-Sales Monitoring
5.2Porters Five Forces Model
5.2.1Overview
5.2.2Bargaining Power of Suppliers
5.2.3Bargaining Power of Buyers
5.2.4The threat of New Entrants
5.2.5Threat of Substitutes
5.2.6Intensity of Rivalry
6Global X-Linked Hypophosphatemia Market, by Treatment
6.1Introduction
6.2Medication
6.3Surgical or Orthopedic Treatment
7Global X-Linked Hypophosphatemia Market, by End User
7.1Introduction
7.2Hospitals and Clinics
7.3Research Centers
8Global X-Linked Hypophosphatemia Market, by Region
8.1Introduction
8.2Americas
8.2.1North America
8.2.1.1US
8.2.1.2Canada
8.2.2South America
8.3Europe
8.3.1Germany
8.3.2France
8.3.3UK
8.3.4Italy
8.3.5Spain
8.3.6Rest of Europe
8.4Asia-Pacific
8.4.1China
8.4.2Japan
8.4.3India
8.4.4South Korea
8.4.5Australia
8.4.6Rest of Asia-Pacific
8.5RoW
9Competitive landscape
9.1Introduction
9.2Key developments
10Company Profiles
10.1Ultragenyx Pharmaceutical
10.1.1Company Overview
10.1.2Financial Overview
10.1.3Products/Services Offered
10.1.4Key Developments
10.1.5SWOT Analysis
10.1.6Key Strategies
10.2Validus Pharmaceuticals LLC
10.2.1Company Overview
10.2.2Financial Overview
10.2.3Products/Services Offered
10.2.4Key Developments
10.2.5SWOT Analysis
10.2.6Key Strategies
10.3Prospec-Tany Technogene Ltd
10.3.1Company Overview
10.3.2Financial Overview
10.3.3Products/Services Offered
10.3.4Key Developments
10.3.5SWOT Analysis
10.3.6Key Strategies
10.4Merck KGaA
10.4.1Company Overview
10.4.2Financial Overview
10.4.3Products/Services Offered
10.4.4Key Developments
10.4.5SWOT Analysis
10.4.6Key Strategies
10.5Zeria Pharmaceutical Co., Ltd
10.5.1Company Overview
10.5.2Financial Overview
10.5.3Products/Services Offered
10.5.4Key Developments
10.5.5SWOT Analysis
10.5.6Key Strategies
10.6Smith & Nephew
10.6.1Company Overview
10.6.2Financial Overview
10.6.3Products/Services Offered
10.6.4Key Developments
10.6.5SWOT Analysis
10.6.6Key Strategies
10.7Narang Medical Limited
10.7.1Company Overview
10.7.2Financial Overview
10.7.3Products/Services Offered
10.7.4Key Developments
10.7.5SWOT Analysis
10.7.6Key Strategies
10.8Eli Lilly and Company
10.8.1Company Overview
10.8.2Financial Overview
10.8.3Products/Services Offered
10.8.4Key Developments
10.8.5SWOT Analysis
10.8.6Key Strategies
10.9F. Hoffmann-La Roche Ltd
10.9.1Company Overview
10.9.2Financial Overview
10.9.3Products/Services Offered
10.9.4Key Developments
10.9.5SWOT Analysis
10.9.6Key Strategies
10.1Illumina, Inc.
10.10.1Company Overview
10.10.2Financial Overview
10.10.3Products/Services Offered
10.10.4Key Developments
10.10.5SWOT Analysis
10.10.6Key Strategies
10.11Biomedica Medizinprodukte GmbH
10.11.1Company Overview
10.11.2Financial Overview
10.11.3Products/Services Offered
10.11.4Key Developments
10.11.5SWOT Analysis
10.11.6Key Strategies
10.12QIAGEN
10.12.1Company Overview
10.12.2Financial Overview
10.12.3Products/Services Offered
10.12.4Key Developments
10.12.5SWOT Analysis
10.12.6Key Strategies
11Appendix
11.1References
11.2Related Reports

List Of Tables



TABLE 1LIST OF ASSUMPTIONS
TABLE 2PORTERS FIVE FORCES ANALYSIS: GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET
TABLE 3GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 4GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET FOR MEDICATION, BY REGION 20162025 (USD THOUSANDS)
TABLE 5GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET FOR SURGICAL OR ORTHOPEDIC TREATMENT, BY REGION 20162025 (USD THOUSANDS)
TABLE 6GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 7GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET FOR HOSPITALS AND CLINICS, BY REGION 20162025 (USD THOUSANDS)
TABLE 8GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET FOR RESEARCH CENTERS, BY REGION 20162025 (USD THOUSANDS)
TABLE 9GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET, BY REGION 20162025 (USD THOUSANDS)
TABLE 10AMERICAS: X-LINKED HYPOPHOSPHATEMIA MARKET, BY REGION 20162025 (USD THOUSANDS)
TABLE 11AMERICAS: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 12AMERICAS: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 13NORTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY COUNTRY 20162025 (USD THOUSANDS)
TABLE 14NORTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 15NORTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 16US: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 17US: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 18CANADA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 19CANADA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 20SOUTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 21SOUTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 22EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY COUNTRY/REGION 20162025 (USD THOUSANDS)
TABLE 23EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 24EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 25GERMANY: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 26GERMANY: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 27FRANCE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 28FRANCE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 29UK: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 30UK: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 31ITALY: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 32ITALY: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 33SPAIN: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 34SPAIN: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 35REST OF EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 36REST OF EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 37ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET, BY COUNTRY/REGION 20162025 (USD THOUSANDS)
TABLE 38ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 39ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 40CHINA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 41CHINA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 42JAPAN: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 43JAPAN: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 44INDIA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 45INDIA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 46SOUTH KOREA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 47SOUTH KOREA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 48ASUTRALIA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 49ASUTRALIA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 50ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 51ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 52ROW: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 20162025 (USD THOUSANDS)
TABLE 53ROW: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 20162025 (USD THOUSANDS)
TABLE 54KEY DEVELOPMENTS, BY PLAYERS IN THE MARKET

List Of Figures



FIGURE 1MARKET SYNOPSIS
FIGURE 2GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET: STRUCTURE
FIGURE 3TOP-DOWN & BOTTOM-UP APPROACH
FIGURE 4MARKET DYNAMICS: ANALYSIS OF THE GLOBAL GROWTH HORMONE MARKET
FIGURE 5DRIVER IMPACT ANALYSIS
FIGURE 6RESTRAINT IMPACT ANALYSIS
FIGURE 7SUPPLY CHAIN: GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET
FIGURE 8GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2018 & 2025 (USD THOUSANDS)
FIGURE 9GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2018 & 2025 (USD THOUSANDS)
FIGURE 10GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET SHARE, BY REGION 2018 (%)
FIGURE 11AMERICAS: X-LINKED HYPOPHOSPHATEMIA MARKET SHARE, BY REGION 2018 (%)
FIGURE 12NORTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET SHARE, BY COUNTRY 2018 (%)
FIGURE 13EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET SHARE, BY COUNTRY/REGION 2018 (%)
FIGURE 14ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET SHARE, BY COUNTRY/REGION 2018 (%)
FIGURE 15MAJOR PLAYERSCATEGORY-WISE SHARE OF KEY DEVELOPMENTS

2020 Global Transfusion Diagnostics Market for 40 Immunohematology and NAT Assays: Americas, EMEA, APAC--A 68-Country Analysis--Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation

This new 68-country report is available by region, country, market segment, section, or individual test. The report is designed to help current suppliers and potential market entrants identify and

USD 45000 View Report

Global Estrogen Replacement Therapy Market by Dosage Forms (Patches, Tablets, Gels/Creams, Suppositories, Implants And Injections), By Routes Of Administration (Oral, Topical, Subcutaneous Pellets, Injections, and Others), By End-User (Hospitals, Clinics, Pharmacy Store, and Others), and By Region (North America, Europe, Asia Pacific, South America, and Middle East & Africa), Forecast from 2020 to 2027

Global Estrogen Replacement Therapy Market by Dosage Forms (Patches, Tablets, Gels/Creams, Suppositories, Implants And Injections), By Routes Of Administration (Oral, Topical, Subcutaneous Pellets, Injections, and Others), By End-User (Hospitals, Clinics, Pharmacy Store, and Others), and By Region (North America, Europe, Asia Pacific, South America, and Middle East & Africa), Forecast from 2020 to 2027 market research report available in single user pdf license with Aarkstore Enterprise at USD 4950

USD 4950 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available